Akebia Therapeutics, Inc.

DB:AX9 Stock Report

Market Cap: €383.7m

Akebia Therapeutics Past Earnings Performance

Past criteria checks 0/6

Akebia Therapeutics has been growing earnings at an average annual rate of 35.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 12.2% per year.

Key information

35.6%

Earnings growth rate

43.5%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-12.2%
Return on equityn/a
Net Margin-27.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Akebia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:AX9 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24170-4610436
30 Jun 24174-4010041
31 Mar 24187-4310153
31 Dec 23195-5210063
30 Sep 23194-5910585
30 Jun 23201-98114100
31 Mar 23271-58119106
31 Dec 22292-94139130
30 Sep 22294-158153127
30 Jun 22294-163168140
31 Mar 22221-276177151
31 Dec 21212-282174148
30 Sep 21211-299170156
30 Jun 21222-300163162
31 Mar 21259-392157178
31 Dec 20295-385154218
30 Sep 20308-391159261
30 Jun 20340-386153289
31 Mar 20351-268153322
31 Dec 19335-280149323
30 Sep 19325-245137330
30 Jun 19286-217113326
31 Mar 19234-19389312
31 Dec 18208-14487291
30 Sep 18238-6840435
30 Jun 18227-6536364
31 Mar 18206-5330292
31 Dec 17181-7427231
30 Sep 1792-127260
30 Jun 1751-140240
31 Mar 1722-154220
31 Dec 162-13622116
30 Sep 160-11822-29
30 Jun 160-10121-13
31 Mar 160-7620-7
31 Dec 150-61180
30 Sep 150-511834
30 Jun 150-411725
31 Mar 150-381524
31 Dec 140-124150
30 Sep 140-1231222
30 Jun 140-1201018
31 Mar 140-164815

Quality Earnings: AX9 is currently unprofitable.

Growing Profit Margin: AX9 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AX9 is unprofitable, but has reduced losses over the past 5 years at a rate of 35.6% per year.

Accelerating Growth: Unable to compare AX9's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AX9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: AX9's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:26
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akebia Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Jonathan AschoffBrean Capital
Jonathan AschoffB. Riley Wealth